Vycor Medical (VYCO) 10-Q 14 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 14, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	VYCOR MEDICAL INC
Entity Central Index Key	1,424,768
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,848,071

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets
Cash	$ 1,010,718	$ 1,891,658
Trade accounts receivable, net of allowance for doubtful accounts of $2,711 and $2,721	113,472	123,815
Inventory	285,289	336,021
Prepaid expenses and other current assets	186,343	217,800
Total Current Assets	1,595,822	2,569,294
Fixed assets, net	479,114	582,434
Intangible and Other assets:
Trademarks	251,157	251,157
Patents, net of accumulated amortization	368,036	345,113
Website, net of accumulated amortization	14,041	12,576
Security deposits	46,919	53,169
Total Intangible and Other assets	680,153	662,015
TOTAL ASSETS	2,755,089	3,813,743
Current Liabilities
Accounts payable	124,566	221,703
Accrued interest	64,436	40,634
Accrued liabilities	287,288	320,927
Derivative liability	0	19,792
Notes payable	315,307	321,785
TOTAL CURRENT LIABILITIES	791,597	924,841
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 243,804 and 235,560 issued and outstanding as at June 30, 2015 and December 31, 2014 respectively	24	24
Common Stock, $0.0001 par value, 25,000,000 shares authorized 10,941,783 and 10,879,899 shares issued and 10,838,449 and 10,776,565 outstanding at June 30, 2015 and December 31, 2014 respectively	1,094	1,088
Additional Paid-in Capital	24,124,693	23,903,793
Treasury Stock (103,334 shares of Common Stock as of June 30, 2015 and December 31, 2014 respectively, at cost)	(1,033)	(1,033)
Accumulated Deficit	(22,309,012)	(21,082,118)
Accumulated Other Comprehensive Income	147,726	67,148
Total Stockholders' Equity	1,963,492	2,888,902
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,755,089	$ 3,813,743

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 2,711	$ 2,721
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	243,804	235,560
Preferred stock, shares outstanding	243,804	235,560
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	25,000,000	25,000,000
Common Stock, shares issued	10,941,783	10,879,899
Common Stock, shares outstanding	10,838,449	10,776,565
Treasury Stock, shares	103,334	103,334

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue	$ 286,018	$ 298,540	$ 614,570	$ 656,662
Cost of Goods Sold	33,981	35,767	85,674	78,724
Gross Profit	252,037	262,773	528,896	577,938
Operating expenses:
Research and development	15,672	37,395	38,898	52,751
Depreciation and Amortization	86,708	98,997	169,357	193,093
General and administrative	607,750	829,989	1,387,052	2,028,240
Total Operating expenses	710,130	966,381	1,595,307	2,274,084
Operating loss	(458,093)	(703,608)	(1,066,411)	(1,696,146)
Other income (expense)
Interest expense: Related Party	0	(33,613)	0	(67,442)
Interest expense: Other	(11,842)	(12,327)	(23,682)	(26,621)
Gain (loss) on foreign currency exchange	17,723	(5,560)	(74,147)	(6,193)
Change in fair value of derivative liability	31,945	(523,277)	19,792	(269,993)
Total Other income (expense)	37,826	(569,217)	(78,038)	(364,056)
Loss Before Provision for Income Taxes	(420,267)	(1,278,385)	(1,144,448)	(2,066,395)
Net Loss	(420,267)	(1,278,385)	(1,144,448)	(2,066,395)
Preferred dividends	0	0	(82,446)	0
Net Loss available to common shareholders	(420,267)	(1,278,385)	(1,266,894)	(2,066,395)
Comprehensive Income (Loss)
Foreign Currency Translation Adjustment	19,076	5,905	(80,577)	6,427
Net Comprehensive Loss	$ (401,191)	$ (1,272,480)	$ (1,307,471)	$ (2,059,968)
Loss Per Share
Basic and diluted	$ (0.04)	$ (0.12)	$ (0.11)	$ (0.21)
Weighted Average Number of Shares Outstanding	10,819,691	10,570,609	10,806,338	9,787,198

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (1,144,448)	$ (2,066,395)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization of intangible assets	41,700	74,944
Depreciation of fixed assets	132,418	125,786
Provision for inventory	15,162
Share based compensation expense	138,460	259,727
(Gain) loss on foreign exchange	74,147	6,193
Change in fair value of derivative liability	(19,792)	269,993
Changes in assets and liabilities:
Accounts receivable	10,342	15,753
Inventory	35,570	(32,747)
Prepaid expenses	65,259	990
Security Deposits	6,250	0
Accounts payable	(97,137)	(68,737)
Accrued interest: Related Party	0	(218,895)
Accrued interest: Other	23,803	(115,868)
Accrued liabilities	(33,638)	(45,550)
Cash used in operating activities	(751,904)	(1,794,806)
Cash flows used in investing activities:
Purchase of fixed assets	(26,486)	(62,001)
Purchase of website	(3,250)	(13,842)
Acquisition of patents	(66,276)	(6,199)
Cash used in investing activities	(96,012)	(82,042)
Cash flows from financing activities:
Proceeds from issuance of Common Stock Offering	0	5,000,000
Repayment of Notes Payable: Related Party	0	(126,519)
Repayment of Notes Payable: Other	(40,280)	(186,716)
Cash provided by financing activities	(40,280)	4,686,765
Effect of exchange rate changes on cash	7,256	(1,168)
Net increase (decrease) in cash	(880,940)	2,808,749
Cash at beginning of period	1,891,658	31,303
Cash at end of period	1,010,718	2,840,052
Supplemental Disclosures of Cash Flow information:
Interest paid:	0	430,208
Preferred stock dividends satisfied in new preferred stock	$ 82,446	$ 0

1. Basis of Presentation

1. Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been condensed or omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2014 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. The condensed consolidated financial statements for the three and six months ended June 30, 2015 and 2014, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and six months ended June 30, 2015 and 2014 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

2. Significant Accounting Polic

2. Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	Principles of Consolidation The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation. Recent Accounting Pronouncements From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented. Derivative Liability The Company has accounted for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they had anti-dilution rights, they did not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classified the warrant instrument as a liability at its fair value and adjusted the instrument to fair value at each reporting period. This liability was subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expired, and was classified in the balance sheet as a current liability. Any change in fair value of the warrant liability was recognized in the Company’s statement of operations as other income (loss). The anti-dilution provisions expired on June 11, 2015 and accordingly the liability has been extinguished. Software Development Costs The authoritative accounting guidance Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: June 30, June 30, 2015 2014 Stock options outstanding 25,557 5,557 Warrants to purchase common stock 6,007,048 5,226,523 Debentures convertible into common stock 202,465 477,716 Preferred shares convertible into common stock 1,148,782 14,815 Total 7,383,851 5,724,611

3. Notes Payable

3. Notes Payable	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
NOTES PAYABLE	As of June 30, 2015 and December 31, 2014, Notes Payable consists of: June 30, 2015 December 31, 2014 On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to December 31, 2015. 300,000 300,000 Insurance policy finance agreements. During the period ended June 30, 2015 the Company made repayments of $40,280. The notes are due over the next twelve months. 15,307     21,785 Total Notes Payable: $ 315,307 $ 321,785 The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.

4. Segment Reporting, Geographi

4. Segment Reporting, Geographical Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	(a) Business segments The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Revenue: Vycor Medical $ 221,258 $ 203,191 $ 480,107 $ 466,902 NovaVision 64,760 95,349 134,463 189,760 Total Revenue $ 286,018 $ 298,540 $ 614,570 $ 656,662 Gross Profit: Vycor Medical $ 193,743 $ 177,717 $ 412,794 $ 411,125 NovaVision 58,294 85,056 116,102 166,813 Total Gross Profit $ 252,037 $ 262,773 $ 528,896 $ 577,938 June 30, 2015 December 31, 2014 Total Assets: Vycor Medical $ 1,728,797 $ 2,644,513 NovaVision 1,026,292 1,169,230 Total Assets $ 2,755,089 $ 3,813,743 (b) Geographic information The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Revenue: United States $ 248,059 $ 238,474 $ 531,998 $ 531,635 Europe 37,959 60,066 82,572 125,027 Total Revenue $ 286,018 $ 298,540 $ 614,570 $ 656,662 Gross Profit: United States $ 217,977 $ 207,577 $ 456,328 $ 465,816 Europe 34,060 55,196 72,568 112,122 Total Gross Profit $ 252,037 $ 262,773 $ 528,896 $ 577,938 June 30, 2015 December 31, 2014 Total Assets: United States $ 2,379,325 $ 3,367,679 Europe 375,764 446,064 Total Assets $ 2,755,089 $ 3,813,743

5. Equity

5. Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
EQUITY	During January to June 2015, the Company issued: 5,377 shares of Common Stock (valued at $10,000) to Steven Girgenti, 6,085 shares of Common Stock (valued at $10,000) to Oscar Bronsther and 6,085 shares of Common Stock (valued at $10,000) to Lowell Rush in consideration for services provided to the Board of Directors; and 1,844 shares of Common Stock (valued at $3,125) to Alvaro Pasual-Leone, 3,687 shares of Common Stock (valued at $6,250) to Josef Zihl and 1,901 shares of Common Stock (valued at $3,125) to each of Jason Barton and Jose Romano in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board. During January to June 2015, in accordance with the terms the Consulting Agreement, the Company issued 16,485 shares of Common Stock (valued at $30,000) to Fountainhead, a related party. During the period ended June 2015, in accordance with the terms of an investor relations advisory agreement, the Company issued 18,519 shares of Common Stock (valued at $33,333) to Acorn Management Partners. During the period ended June 2015 Preferred D Stock, convertible into shares of Common Stock, was issued in respect of Preferred Dividends as follows: 5,745 shares of Preferred D Stock, convertible into 26,721 shares of Common Stock (valued at $57,453) to Fountainhead; 2,119 shares of Preferred D Stock, convertible into 9,856 shares of Common Stock (valued at $21,194) to Peter Zachariou; and 380 shares of Preferred D Stock, convertible into 1,767 shares of Common Stock (valued at $3,799) to Craig Kirsch. Warrants and Options The details of the outstanding warrants and options are as follows: STOCK WARRANTS: Number of shares Weighted average exercise price per share Outstanding at December 31, 2013 1,404,599 $ 3.39 Granted 5,226,120 2.61 Exercised - - Cancelled or expired (719,004 ) 4.46 Outstanding at December 31, 2014 5,911,715 $ 2.57 Granted 100,000 2.56 Exercised - - Cancelled or expired (4,667 ) - Outstanding at June 30, 2015 6,007,048 $ 2.57 STOCK OPTIONS: Number of shares Weighted average exercise price per share Outstanding at December 31, 2013 5,557 $ 20.25 Granted 20,000 $ 2.00 Exercised - - Cancelled or expired - - Outstanding at December 31, 2014 25,557 $ 5.97 Granted - - Exercised - - Cancelled or expired - - Outstanding at June 30, 2015 25,557 $ 5.97 As of June 30, 2015, the weighted-average remaining contractual life of outstanding warrants and options is 1.76 and 2.69 years, respectively.

6. Share-Based Compensation

6. Share-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	Stock Option Plan The Company adopted the Vycor Medical, Inc. Employee, Director, and Consultant Stock Plan (the “Plan”) as of February 13, 2008. The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company. The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code. Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date. The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date. The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years. The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis. Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis. For the period ended June 30, 2015 and 2014, the Company recognized share-based compensation of $25,011 and $0, respectively, for employee stock options. Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan. As of June 30, 2015 there were no awards of any stock appreciation rights. Non-Employee Stock Compensation 6 months ended June 30, 2015 Name Description $ in period Steven Girgenti 5,377 shares issued for services rendered to the board of directors $ 10,000 Oscar Bronsther 6,085 shares issued for services rendered to the board of directors $ 10,000 Lowell Rush 6,085 shares issued for services rendered to the board of directors $ 10,000 Alvaro Pascual-Leone 1,844 shares issued for services rendered to the Scientific Advisory Board $ 3,125 Jason Barton 1,901 shares issued for services rendered to the Scientific Advisory Board $ 3,125 Jose Romano 1,901 shares issued for services rendered to the Scientific Advisory Board $ 3,125 Josef Zihl 3,687 shares issued for services rendered to the Scientific Advisory Board $ 6,250 Fountainhead Capital Mgmt 16,485 shares issued in accordance with the terms of the consulting agreement $ 30,000 Acorn Management Partners 18,519 shares issued in relation to an investor advisory agreement $ 33,333 Gordon Holmes 100,000 warrants issued in relation to investor advisory agreement $ 4,492 Total Compensation $ 113,450 Totals and Fair Values Aggregate stock-based compensation expense charged to operations for stock and warrants granted to the employees and non-employees for the three and six months ended June 30, 2015 was $50,310 and $138,460. As of June 30, 2015, there was $0 of total unrecognized compensation costs related to warrant and stock awards and non-vested options. Stock-based compensation expenses related to common stock, options and warrants granted to employees and non-employees are recognized as the services are received or the stock, options and warrants are earned. The common stock, options or warrants meet the criteria for equity treatment and their fair is estimated at the grant date. Expense related to common stock is recognized on a straight-line basis over the period during which services are to be received; expense related to options and warrants is recognized on a straight-line basis over the shorter of the period during which services are to be received or the life of the option or warrant. The fair value of the common stock is determined by the then-prevailing share price. The grant date fair value of the options and warrants is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, using the assumptions noted in the table below. Expected volatility is based on the historical volatility of a peer group of publicly traded companies. The following assumptions were used in calculations of the Black-Scholes option pricing model for the six months ended June 30, 2015 and 2014: Six months ended June 30, 2015 2014 Risk-free interest rates 1.07 % 0.78 % Expected life 3 years 3 years Expected dividends 0 % 0 % Expected volatility 101 % 75 % Vycor Common Stock fair value $ 2.00 $ 2.05

7. Fair Value Measurements

7. Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	The Company has adopted ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The adoption of ASC 820 did not have an impact on the Company’s financial position or results of operations. Under the terms of the Offering, during the period January 2 to April 25, 2014, in five separate closings, a total of 2,397,631 Series A Warrants and Placement Agent Warrants were issued, which carried anti-dilution rights. Effective May 15, 2014 these anti-dilution rights were waived for all but 34,723 of the Series A Warrants and for all of the Placement Agent Warrants. The Company has accounted for the Series A Warrants in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they had anti-dilution rights, they did not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classified the warrant instrument as a liability at its fair value and adjusted the instrument to fair value at each reporting period. Effective June 11, 2015 the anti-dilution provisions of these remaining 34,723 Warrants expired and accordingly the liability has been extinguished. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis (the Series A Warrants described above) as of June 30, 2015 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the liability, and includes situations where there is little, if any, market activity for the liability: Description June 30, 2015 Level 1 Level 2 Level 3 Warrant Liability $ - $ - $ - $ - The table below provides a reconciliation of the beginning and ending balances for the liabilities measured using fair significant unobservable inputs (Level 3): Balance at January 1, 2015 $ 19,792 Change in fair value to June 11, 2015 485 Extinguishment of liability June 11, 2015 (20,277 ) Balance at June 30, 2015 $ - The fair value of the Series A Warrants and Placement Agent Warrants was determined using a Monte Carlo Simulation. This model requires the input of highly subjective assumptions, including the expected price volatility, which is based on the historical volatility of a peer group of publicly traded companies. Changes in the subjective input assumptions can materially affect the estimate of fair value of the warrants and the Company’s results of operations could be impacted. The following assumptions were used in calculations of the Monte Carlo Simulation model for the six months ended June 30, 2015 and 2014: Six months ended June 30, 2015 2014 Risk-free interest rates 0.56-.73 % 0.68-0.93 % Expected life 1.65 years 3 years Expected dividends 0 % 0 % Expected volatility 90-93 % 71-83 % Vycor Common Stock fair value $ 1.59-1.84 $ 1.88-2.39

8. Commitments and Contingencie

8. Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Lease The Company leases approximately 10,000 sq. ft located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,260 plus sales tax per month. The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the six months ended June 30, 2015 and 2014 was $97,973 and $99,160 respectively. Potential German tax liability In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. The tax authorities have agreed to suspend the assessment pending the outcome of certain court hearings, and the Company has agreed to make limited monthly payments on account. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the three and six months ending June 30, 2015, other than recording the monthly payments as an expense. Potential Patent Infringement The Company was made aware in 2012 that a competitor had been granted a patent for related technology, and appeared to be entering the market with products that infringe the Company’s own issued patent. Following investigation, the Company has taken steps to initiate an invalidation of the competitor’s patent and enforce its patent rights; in March 2014 the Patent Re-examination Board issued an Examination Decision invalidating all the claims of the competitor’s patent. The competitor has the right of appeal but the Company will contest any such appeal. The Company has also been made aware that a second competitor has filed a patent application for related technology and also may be producing a product that potentially infringes the Company’s patent, and is in the early stages of evaluation and has yet to determine what, if any actions to take in this instance, however as a general rule the Company intends to take all necessary action to protect its patent portfolio. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.

9. Consulting and Other Agreeme

9. Consulting and Other Agreements	6 Months Ended
	Jun. 30, 2015
Consulting and Other Agreements [Abstract]
CONSULTING AND OTHER AGREEMENTS	The following agreements were entered into or remained in force during the six months ended June 30, 2015: Under the terms of an amended Consulting Agreement between the Company and Fountainhead, Fountainhead is paid a monthly retainer of $10,000 per month, payable $5,000 in cash and $5,000 payable in Company Common Stock at the end of each quarter. In January 2015, as amended in May 2015, the Company entered into a twelve (12) month agreement, subject to early termination, to provide financial advisory, strategic business planning and professional relations services, with Acorn Management Partners (“Acorn”). Under the terms of the Acorn Agreement, Acorn receives $8,000 in cash per month and 25,000 shares of Restricted Common Stock (at the absolute discretion of the Company) in the first two three month periods and $8,000 in cash per month and 75,000 shares of restricted common stock in the final two three month periods. In March 2015, the Company entered into a twelve (12) month agreement to provide investor relations services with Gordon Holmes. Under the terms of the agreement, Gordon Holmes received warrants to purchase 100,000 Vycor shares of Common Stock at $2.56, exercisable for a period of three years.

10. Related Party Transactions

10. Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	Through June 30 2015, in accordance with the terms of the Consulting Agreement, the Company issued 16,485 shares of Common Stock (valued at $30,000) to Fountainhead. During the period ended March 2015 Preferred D Stock, convertible into shares of Common Stock, was issued in respect of Preferred Dividends as follows: 5,745 shares of Preferred D Stock, convertible into 26,721 shares of Common Stock (valued at $57,453) to Fountainhead; and 2,119 shares of Preferred D Stock, convertible into 9,856 shares of Common Stock (valued at $21,194) to Peter Zachariou.

11. Subsequent Events

11. Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	The Company evaluated subsequent events through the date the financial statements were issued and filed with this Form 10Q: Share Issuance During July to August 2015, the Company issued 3,425 shares of Common Stock (valued at $5,000) to Steven Girgenti, in consideration for services provided to the Board of Directors and 1,184 and 2,367 shares of Common Stock respectively (valued at $1,563 and $3,125 respectively) to Alvaro Pascual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board. During August 2015 Preferred D Stock, convertible into shares of Common Stock at $2.15, was issued in respect of Preferred Dividends as follows: 5,946 shares of Preferred D Stock, convertible into 27,656 shares of Common Stock (valued at $59,463) to Fountainhead; 2,194 shares of Preferred D Stock, convertible into 10,205 shares of Common Stock (valued at 21,936) to Peter Zachariou; and 393 shares of Preferred D Stock, convertible into 1,828 shares of Common Stock (valued at $3,932) to Craig Kirsch. During August 2015, the Company entered into a new consulting agreement with Liolios Group, Inc. to perform certain investor related activities and issued 2,646 shares of Common Stock (valued at $3,333).

2. Significant Accounting Pol17

2. Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
Recent Accounting Pronouncements	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Derivative Liability	The Company has accounted for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they had anti-dilution rights, they did not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classified the warrant instrument as a liability at its fair value and adjusted the instrument to fair value at each reporting period. This liability was subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expired, and was classified in the balance sheet as a current liability. Any change in fair value of the warrant liability was recognized in the Company’s statement of operations as other income (loss). The anti-dilution provisions expired on June 11, 2015 and accordingly the liability has been extinguished.
Software Development Costs	The authoritative accounting guidance
Net Loss Per Share	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: June 30, June 30, 2015 2014 Stock options outstanding 25,557 5,557 Warrants to purchase common stock 6,007,048 5,226,523 Debentures convertible into common stock 202,465 477,716 Preferred shares convertible into common stock 1,148,782 14,815 Total 7,383,851 5,724,611

2. Significant Accounting Pol18

2. Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	June 30, June 30, 2015 2014 Stock options outstanding 25,557 5,557 Warrants to purchase common stock 6,007,048 5,226,523 Debentures convertible into common stock 202,465 477,716 Preferred shares convertible into common stock 1,148,782 14,815 Total 7,383,851 5,724,611

3. Notes Payable (Tables)

3. Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Components of notes payable	June 30, 2015 December 31, 2014 On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to December 31, 2015. 300,000 300,000 Insurance policy finance agreements. During the period ended June 30, 2015 the Company made repayments of $40,280. The notes are due over the next twelve months. 15,307     21,785 Total Notes Payable: $ 315,307 $ 321,785

4. Segment Reporting, Geograp20

4. Segment Reporting, Geographical Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of business segments information	Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Revenue: Vycor Medical $ 221,258 $ 203,191 $ 480,107 $ 466,902 NovaVision 64,760 95,349 134,463 189,760 Total Revenue $ 286,018 $ 298,540 $ 614,570 $ 656,662 Gross Profit: Vycor Medical $ 193,743 $ 177,717 $ 412,794 $ 411,125 NovaVision 58,294 85,056 116,102 166,813 Total Gross Profit $ 252,037 $ 262,773 $ 528,896 $ 577,938 June 30, 2015 December 31, 2014 Total Assets: Vycor Medical $ 1,728,797 $ 2,644,513 NovaVision 1,026,292 1,169,230 Total Assets $ 2,755,089 $ 3,813,743
Summary of geographic information	Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Revenue: United States $ 248,059 $ 238,474 $ 531,998 $ 531,635 Europe 37,959 60,066 82,572 125,027 Total Revenue $ 286,018 $ 298,540 $ 614,570 $ 656,662 Gross Profit: United States $ 217,977 $ 207,577 $ 456,328 $ 465,816 Europe 34,060 55,196 72,568 112,122 Total Gross Profit $ 252,037 $ 262,773 $ 528,896 $ 577,938 June 30, 2015 December 31, 2014 Total Assets: United States $ 2,379,325 $ 3,367,679 Europe 375,764 446,064 Total Assets $ 2,755,089 $ 3,813,743

5. Equity (Tables)

5. Equity (Tables)	6 Months Ended
	Jun. 30, 2015
Warrant [Member]
Derivative [Line Items]
Schedule of warrants and options	STOCK WARRANTS: Number of shares Weighted average exercise price per share Outstanding at December 31, 2013 1,404,599 $ 3.39 Granted 5,226,120 2.61 Exercised - - Cancelled or expired (719,004 ) 4.46 Outstanding at December 31, 2014 5,911,715 $ 2.57 Granted 100,000 2.56 Exercised - - Cancelled or expired (4,667 ) - Outstanding at June 30, 2015 6,007,048 $ 2.57
Stock Option [Member]
Derivative [Line Items]
Schedule of warrants and options	Schedule STOCK OPTIONS: Number of shares Weighted average exercise price per share Outstanding at December 31, 2013 5,557 $ 20.25 Granted 20,000 $ 2.00 Exercised - - Cancelled or expired - - Outstanding at December 31, 2014 25,557 $ 5.97 Granted - - Exercised - - Cancelled or expired - - Outstanding at June 30, 2015 25,557 $ 5.97

6. Share-Based Compensation (Ta

6. Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of non-employee stock compensation	6 months ended June 30, 2015 Name Description $ in period Steven Girgenti 5,377 shares issued for services rendered to the board of directors $ 10,000 Oscar Bronsther 6,085 shares issued for services rendered to the board of directors $ 10,000 Lowell Rush 6,085 shares issued for services rendered to the board of directors $ 10,000 Alvaro Pascual-Leone 1,844 shares issued for services rendered to the Scientific Advisory Board $ 3,125 Jason Barton 1,901 shares issued for services rendered to the Scientific Advisory Board $ 3,125 Jose Romano 1,901 shares issued for services rendered to the Scientific Advisory Board $ 3,125 Josef Zihl 3,687 shares issued for services rendered to the Scientific Advisory Board $ 6,250 Fountainhead Capital Mgmt 16,485 shares issued in accordance with the terms of the consulting agreement $ 30,000 Acorn Management Partners 18,519 shares issued in relation to an investor advisory agreement $ 33,333 Gordon Holmes 100,000 warrants issued in relation to investor advisory agreement $ 4,492 Total Compensation $ 113,450
Schedule of assumptions used in calculations of the Black-Scholes option pricing model	Six months ended June 30, 2015 2014 Risk-free interest rates 1.07 % 0.78 % Expected life 3 years 3 years Expected dividends 0 % 0 % Expected volatility 101 % 75 % Vycor Common Stock fair value $ 2.00 $ 2.05

7. Fair Value Measurements (Tab

7. Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule liabilities measured at fair value on a recurring basis	Description June 30, 2015 Level 1 Level 2 Level 3 Warrant Liability $ - $ - $ - $ -
Schedule of liabilities measured using fair significant unobservable inputs (Level 3)	Balance at January 1, 2015 $ 19,792 Change in fair value to June 11, 2015 485 Extinguishment of liability June 11, 2015 (20,277 ) Balance at June 30, 2015 $ -
Schedule of fair value assumptions used in calculation of the Monte Carlo Simulation model	Six months ended June 30, 2015 2014 Risk-free interest rates 0.56-.73 % 0.68-0.93 % Expected life 1.65 years 3 years Expected dividends 0 % 0 % Expected volatility 90-93 % 71-83 % Vycor Common Stock fair value $ 1.59-1.84 $ 1.88-2.39

2. Significant Accounting Pol24

2. Significant Accounting Policies (Details) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	7,383,851	5,724,611
Stock Option Plan [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	25,557	5,557
Warrant [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	6,007,048	5,226,523
Debentures Convertible
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	202,465	477,716
Convertible Preferred Stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,148,782	14,815

2. Significant Accounting Pol25

2. Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Significant Accounting Policies
Estimated useful life of software	5 years	5 years
Software and Software Development Costs [Member]
Significant Accounting Policies
Capitalized software development cost additions	$ 26,486	$ 55,039

3. Notes Payable (Details)

3. Notes Payable (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Components of notes payable
Total Related Party Notes Payable:	$ 315,307	$ 321,785
Term Note [Member]
Components of notes payable
Total Related Party Notes Payable:	300,000	21,785
Insurance Policy Finance Agreements [Member]
Components of notes payable
Total Related Party Notes Payable:	$ 15,307	$ 300,000

4. Segment Reporting, Geograp27

4. Segment Reporting, Geographical Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)
Revenue:
Total Revenue	$ 286,018	$ 298,540	$ 614,570	$ 656,662
Gross Profit:
Total Gross Profit	252,037	262,773	528,896	577,938
Total Assets:
Total Assets	2,755,089		2,755,089		$ 3,813,743
Vycor Medical [Member]
Revenue:
Total Revenue	221,258	203,191	480,107	466,902
Gross Profit:
Total Gross Profit	193,743	177,717	412,794	411,125
Total Assets:
Total Assets	1,728,797		1,728,797			€ 2,644,513
Novavision [Member]
Revenue:
Total Revenue	64,760	95,349	134,463	189,760
Gross Profit:
Total Gross Profit	58,924	$ 85,056	166,813	$ 166,813
Total Assets:
Total Assets	$ 1,026,292		$ 1,026,292			€ 1,169,230

4. Segment Reporting, Geograp28

4. Segment Reporting, Geographical Information (Details 1)	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)
Revenue:
Total Revenue	$ 286,018	$ 298,540	$ 614,570	$ 656,662
Gross Profit:
Total Gross Profit	252,037	262,773	528,896	577,938
Total Assets:
Total Assets	2,755,089		2,755,089		$ 3,813,743
United States
Revenue:
Total Revenue	248,059	238,474	531,998	531,635
Gross Profit:
Total Gross Profit	217,977	207,577	456,328	465,816
Total Assets:
Total Assets	2,379,325		2,379,325			€ 3,367,679
Europe [Member]
Revenue:
Total Revenue	37,959	60,066	82,572	125,027
Gross Profit:
Total Gross Profit	34,060	$ 55,196	72,568	$ 112,122
Total Assets:
Total Assets	$ 375,764		$ 375,764			€ 446,064

5. Equity (Details)

5. Equity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Warrant [Member]
Details of the outstanding rights, options and warrants and value of such rights, options and warrants
Options Outstanding, Beginning Balance	5,911,715	1,404,599
Number of shares, Granted	100,000	5,226,120
Number of shares, Exercised	0	0
Number of shares, Cancelled or expired	(4,667)	(719,004)
Options Outstanding, Ending Balance	6,007,048	5,911,715
Weighted average exercise price per share, Outstanding, Beginning Balance	$ 2.57	$ 3.39
Weighted average exercise price per share, Granted	2.56	2.61
Weighted average exercise price per share, Exercised	0	0
Weighted average exercise price per share, Cancelled or expired	0	4.46
Weighted average exercise price per share, Outstanding, Ending balance	$ 2.57	$ 2.57
Stock Option [Member]
Details of the outstanding rights, options and warrants and value of such rights, options and warrants
Options Outstanding, Beginning Balance	25,557	5,557
Number of shares, Granted	0	20,000
Number of shares, Exercised	0	0
Number of shares, Cancelled or expired	0	0
Options Outstanding, Ending Balance	25,557	25,557
Weighted average exercise price per share, Outstanding, Beginning Balance	$ 5.97	$ 20.25
Weighted average exercise price per share, Granted	0	2
Weighted average exercise price per share, Exercised	0	0
Weighted average exercise price per share, Cancelled or expired	0	0
Weighted average exercise price per share, Outstanding, Ending balance	$ 5.97	$ 5.97

5. Equity (Details Narrative)

5. Equity (Details Narrative) - Jun. 30, 2015 - USD ($)	Total
Equity
Common stock issued value	$ 113,450
Steven Girgenti [Member]
Equity
Common stock issued shares	5,377
Common stock issued value	$ 10,000
Fountainhead [Member]
Equity
Common stock issued shares	16,485
Common stock issued value	$ 30,000
Acorn Management Partners [Member]
Equity
Common stock issued shares	18,519
Common stock issued value	$ 33,333
Oscar Bronsther [Member]
Equity
Common stock issued shares	6,085
Common stock issued value	$ 10,000
Lowell Rush [Member]
Equity
Common stock issued shares	6,085
Common stock issued value	$ 10,000
Alvaro Pascual Leone [Member]
Equity
Common stock issued shares	1,844
Common stock issued value	$ 3,125
Josef Zihl [Member]
Equity
Common stock issued shares	3,687
Common stock issued value	$ 6,250
Jose Romano [Member]
Equity
Common stock issued shares	1,901
Common stock issued value	$ 3,125
Jason Barton [Member]
Equity
Common stock issued shares	1,901
Common stock issued value	$ 3,125
Gordon Holmes [Member]
Equity
Common stock issued value	$ 4,492
Series D Preferred Stock Fountainhead [Member]
Equity
Convertible preferred stock, Shares issued upon conversion	26,721
Series D Preferred Stock [Member] | Fountainhead [Member]
Equity
Common stock issued shares	5,745
Common stock issued value	$ 57,453
Series D Preferred Stock [Member] | Peter Zachariou [Member]
Equity
Common stock issued shares	9,856
Common stock issued value	$ 21,194
Convertible preferred stock, Shares issued upon conversion	9,856
Series D Preferred Stock [Member] | Craig Kirsch [Member]
Equity
Common stock issued shares	380
Common stock issued value	$ 3,799
Convertible preferred stock, Shares issued upon conversion	1,767

6. Share-Based Compensation (De

6. Share-Based Compensation (Details)	6 Months Ended
	Jun. 30, 2015USD ($)
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	$ 113,450
Alvaro Pascual Leone [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	3,125
Fountainhead [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	30,000
Steven Girgenti [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	10,000
Oscar Bronsther [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	10,000
Lowell Rush [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	10,000
Gordon Holmes [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	4,492
Josef Zihl [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	6,250
Jose Romano [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	3,125
Jason Barton [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	3,125
Acorn Management Partners [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	$ 33,333

6. Share-Based Compensation (32

6. Share-Based Compensation (Details 1) - Employee Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Options and warrants expensed
Risk-free interest rates	1.07%	0.78%
Expected life	3 years	3 years
Expected dividends	0.00%	0.00%
Expected volatility	101.00%	75.00%
Vycor Common Stock fair value	$ 2	$ 2.05

6. Share-Based Compensation (33

6. Share-Based Compensation (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014
Share-Based Compensation (Textual)
Share-based compensation	$ 50,310	$ 138,460
Employee Stock Option [Member]
Share-Based Compensation (Textual)
Share-based compensation		$ 25,011	$ 0

7. Fair Value Measurements (Det

7. Fair Value Measurements (Details)	Jun. 30, 2015USD ($)	Jun. 30, 2015EUR (€)	Dec. 31, 2014USD ($)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability	$ 0		$ 19,792
Fair Value, Inputs, Level 1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability | €		€ 0
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability	$ 0		$ 19,792

7. Fair Value Measurements (D35

7. Fair Value Measurements (Details 1)	6 Months Ended
	Jun. 30, 2015USD ($)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Balance at January 1, 2015	$ 19,792
Balance at June 30, 2015	0
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Balance at January 1, 2015	19,792
Change in fair value during period	485
Extinguishment of liability June 11, 2015	(20,277)
Balance at June 30, 2015	$ 0

7. Fair Value Measurements (D36

7. Fair Value Measurements (Details 2) - Warrant [Member] - $ / shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Fair Value Assumptions [Abstract]
Risk-free interest rates, minimum	0.56%	0.68%
Risk-free interest rates, maximum	0.73%	0.93%
Expected life	1 year 7 months 24 days	3 years
Expected dividends	0.00%	0.00%
Expected volatility, minimum	90.00%	71.00%
Expected volatility, maximum	93.00%	83.00%
Vycor common stock fair value minimum	$ 1.59	$ 1.88
Vycor common stock fair value maximum	$ 1.84	$ 2.39

8. Commitments and Contingenc37

8. Commitments and Contingencies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Commitments and Contingencies
Rent expense	$ 97,973	$ 99,160